According to Boqian New Materials's announcement, the company's shareholding company Huchuang Medical plans to increase capital and expand its shares. The registered capital will increase from 153.593.51 million yuan to 15.7516.21 million yuan, and the additional registered capital of 442.27 million yuan will be pledged by the new shareholders Shanghai Meili Enterprise Management Partnership and Henghe Material Technology Co., Ltd. in currencies of 16 million yuan and 10 million yuan respectively. The company and other original shareholders relinquished their priority subscription rights for this capital increase. After the capital increase was completed, the company's shareholding ratio dropped from 9.1463% to 8.8895%. This transaction constitutes a related transaction and does not constitute a major asset restructuring. It has been reviewed and approved by the company's board of directors, and there is no need to submit it to the shareholders' meeting for review.

According to Boqian New Materials's announcement, the company's shareholding company Huchuang Medical plans to increase capital and expand its shares. The registered capital will increase from 153.593.51 million yuan to 15.7516.21 million yuan, and the additional registered capital of 442.27 million yuan will be pledged by the new shareholders Shanghai Meili Enterprise Management Partnership and Henghe Material Technology Co., Ltd. in currencies of 16 million yuan and 10 million yuan respectively. The company and other original shareholders relinquished their priority subscription rights for this capital increase. After the capital increase was completed, the company's shareholding ratio dropped from 9.1463% to 8.8895%. This transaction constitutes a related transaction and does not constitute a major asset restructuring. It has been reviewed and approved by the company's board of directors, and there is no need to submit it to the shareholders' meeting for review.